Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin–Activin–Follistatin–IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study
Authors' conclusion
Short-term liraglutide treatment reduces total and regional mass without altering relative body composition. Further research is warranted to confirm and clarify the clinical significance of these changes, to further study hormonal changes and identify strategies to preserve muscle mass during weight loss.
Study context
- Population
- Adults with obesitycrossover
- Participants
- 20 adults
- Comparison
- Liraglutide 3.0 mg/day vs placebo for 35 days
- Primary endpoint
- Total and regional body composition by DXA
- Follow-up
- End of each phase
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Body composition (DXA) · treatment completion
- Liraglutide reduced body weight, BMI, and total and regional mass (trunk, hip, extremities)
- Absolute fat-free mass slightly but significantly lower
- Absolute lean mass in trunk and extremities decreased
- Relative lean mass and fat-free mass percentages remained stable
Original publication
Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin–Activin–Follistatin–IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study. Diabetes Res Clin Pract. Published 20 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →